(0) items in cart / view cart / checkout  
 
  Chemicals
  Company Profiles
  Country Analyses
  Energy and Utilities
  Food & Beverage
  In Vitro Diagnostics
  Medical Devices
  Pharmaceuticals & Biotechnology
 
 
  Advertising
Aerospace, Defense
Automotive
Banking
Biotechnology
Business Services
Chemicals
Company Reports
Construction
Consumer Goods
Countries
Diagnostics
Energy, Environment
Food & Beverages
Government
Healthcare
IT
Manufacturing
Media
Medical Devices
Pharmaceuticals
Retailing
Sales & Marketing
Sourcing
Telecommunications
Transportation
Travel, Entertainment
 
Home > In Vitro Diagnostics Clinical Chemistry >  Analysis of the Chinese Clinical Chemistry and Immunodiagnostic Markets--Sales Forecasts and Competitive Strategies

Analysis of the Chinese Clinical Chemistry and Immunodiagnostic Markets--Sales Forecasts and Competitive Strategies




“2021 Analysis of the Chinese Clinical Chemistry and Immunodiagnostic Markets” is a new strategic analysis of the major business opportunities emerging in the Chinese clinical chemistry and immunodiagnostic markets during the next five years.  The report provides specimen, test volume and sales forecasts; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.

The report presents five-year test volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays as well as controls, calibrators and consumables.

Rationale

The Chinese clinical chemistry and immunodiagnostics market is undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.  Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology.  This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.

Tests Analyzed in the Report

Routine Clinical Chemistry

Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total, BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride, Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose, HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus, Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid.

Therapeutic Drug Monitoring (TDM)

Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam,
Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.

Endocrine Function

Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,
Prolactin, T3, T3 Uptake,  Free T3, T4, Free T4, TBG, Testosterone,
Thyroglobulin Ab,  TPO Ab, TSH.

Tumor Markers and Special Chemistry

AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid),
Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,
PAP, PSA, Thyroglobulin, Vitamin B-12.

Immunoproteins

C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,
Immunofixation, Prealbumin, Protein Electrophoresis.

Drugs of Abuse

Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,
LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP),
Propoxyphene, Tricyclic Antidepressants.

Current and Emerging Products

- Analysis of current and emerging clinical chemistry
and immunodiagnostic tests.

- Review of current instrumentation technologies, and feature comparison
of high-, medium-, and low-volume/POC analyzers.

Technology Assessment

- Assessment of current and emerging
technologies, and their potential  market applications.

- Comprehensive lists of companies developing
or marketing new technologies and products, by test.

Strategic Recommendations

- New product development opportunities
  with significant market appeal.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Competitive Assessments

- Strategic assessments of major suppliers and
emerging market entrants, including their sales, product
portfolios, marketing tactics, collaborative
arrangements and new products in R&D. 

- The companies analyzed in the report include
Abbott, AdnaGen, Agilent, Alere, Beckman Coulter/Danaher,
Biomedical Diagnostics, bioMerieux, Bio-Rad, DiaSorin,
Eiken, Fujirebio/Innogenetics, IL, Kyowa Medex,
Ortho-Clinical Diagnotics, Roche, Siemens, Sysmex,
Thermo Fisher, Tosoh, Wako, Wallac/PE.

Contains 517 pages and 65 tables



To order sections of this report, contact Client Services


     
   
Local PDF: $2500.00
Other Formats: Global PDF, DataPack
   
   
 
VPGMarketResearch.com © Copyright 2015. all rights reserved. Web Design by Spida Design  
  Close  X